- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Pooled Analysis Reinforces Long-Term Survival Benefit With Ipilimumab
October 2nd 2013, 6:52am
Results from a pooled analysis of data from 12 studies has demonstrated a long-term survival benefit that extends through at least 10 years for patients with advanced melanoma treated with ipilimumab.
Dr. Crinò on Crizotinib in ALK-Positive NSCLC
October 1st 2013, 10:41am
Lucio Crinò, MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer
Additional OS and PFS Benefits Seen With Aflibercept in Post-Hoc VELOUR Analysis
October 1st 2013, 8:02am
A post-hoc analysis of the VELOUR trial demonstrated additional improvements in both overall survival and progression-free survival in favor of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer
Dr. Hudis on BOLERO-3 Trial Biomarker Observations
October 1st 2013, 7:59am
Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, attending physician, Memorial Sloan-Kettering Cancer Center, comments on exploratory biomarker observations from the BOLERO-3 trial.
Dual HER2 Blockade Less Effective in PI3KCA-Mutant Breast Cancer
October 1st 2013, 7:33am
Breast cancer patients with PI3KCA mutations are less likely to achieve a pathological complete response from dual HER2 blockade in the neoadjuvant setting.
Enzalutamide Plus Abiraterone May Have Higher Response Rate in mCRPC Than Either Agent Alone
October 1st 2013, 7:08am
Co-targeting metastatic castrate resistant prostate cancer with the combination of enzalutamide plus abiraterone acetate may circumvent the compensatory mechanisms observed with either agent alone and lead to more profound suppression of androgen signaling.
Dr. Grünwald on Dovitinib Versus Sorafenib in mRCC
September 30th 2013, 4:44pm
Viktor Grünwald, MD, PhD, from the Hannover Medical School, discusses a phase III trial that compared dovitinib to sorafenib for patients with mRCC following prior treatment with one VEGF inhibitor and one mTOR inhibitor.
Dr. Camidge on a Phase I Study With AZD9291 in NSCLC
September 30th 2013, 10:03am
D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses a phase I study looking at AZD9291 in patients with non-small cell lung cancer.
Novel ALK Inhibitor Shows Promise Against Brain Metastasis in NSCLC
September 30th 2013, 9:13am
The first-in-human phase I/II dose-finding study of a novel ALK/EGFR inhibitor called AP26113 demonstrated promising results in both crizotinib-resistant and crizotinib-naïve patients with non-small cell lung cancer.
Survival Benefit Observed With Cetuximab in RAS Wild-Type Colorectal Cancer
September 30th 2013, 8:28am
Cetuximab plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mutations.
Dr. George on Critical Clinical Trials in Kidney Cancer
September 30th 2013, 8:11am
Daniel J. George, MD, Director, GU Oncology, Duke Cancer Institute, discusses critical phase III clinical trials in metastatic renal cell carcinoma.
BOLERO-3 Biomarker Study Provides Clues for Response to Everolimus
September 30th 2013, 7:19am
Exploratory analysis of biomarkers in the BOLERO-3 trial suggests that the addition of everolimus to trastuzumab plus vinorelbine for HER2-positive advanced breast cancer may be most beneficial in patients with low PTEN or high pS6 levels.
OS Comparable for Panitumumab and Cetuximab in KRAS Wild-Type mCRC
September 29th 2013, 9:20am
Panitumumab proved noninferior to cetuximab in extending overall survival in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.
PD-L1 Inhibitor Delivers Rapid, Durable Responses in Advanced NSCLC
September 29th 2013, 8:35am
A phase I study has shown remarkable and durable responses with the engineered monoclonal antibody MPDL3280A in metastatic non-small cell lung cancer, including tumors with squamous and adenocarcinoma histology.
T-DM1 Extends PFS in Heavily Pretreated Advanced Breast Cancer
September 29th 2013, 8:05am
T-DM1 extended progression-free survival compared with "physician's choice of treatment" in women with metastatic HER2-positive breast cancer.
Dr. Marc Peeters on the Aflibercept Toxicity Profile
July 9th 2013, 11:58am
ESMO Gastrointestinal Cancers Congress
Marc Peeters, MD, PhD, from the Antwerp University Hospital, discusses the importance of properly managing the toxicities associated with aflibercept when treating patients with metastatic colorectal cancer.
IV Calcium/Magnesium Has No Effect on Oxaliplatin-Induced Neuropathy
July 6th 2013, 10:19am
ESMO Gastrointestinal Cancers Congress
Intravenous calcium plus magnesium given before or after adjuvant FOLFOX chemotherapy has absolutely no effect on the development of sensory neurotoxicity induced by oxaliplatin.
Dr. Lenz Explores KRAS/NRAS Mutations in Colorectal Cancer
July 6th 2013, 9:22am
ESMO Gastrointestinal Cancers Congress
Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, discusses the potential predictive impact of KRAS and NRAS mutations in metastatic colorectal cancer.
Simple, Inexpensive Blood Test Poised to Be a Real "Game Changer" in CRC Screening
July 6th 2013, 7:24am
ESMO Gastrointestinal Cancers Congress
A simple and inexpensive blood test is being developed that can be used to screen patients for premalignant colorectal cancer lesions which, once perfected, will be a real game changer.
Better Responders in VELOUR Derive Enhanced Benefit From Aflibercept
July 6th 2013, 7:08am
ESMO Gastrointestinal Cancers Congress
Better responders within a cohort of patients from the VELOUR study derive enhanced benefit from aflibercept when combined with FOLFIRI, a post-hoc analysis of the study shows.